

# Gema Moreno-Bueno

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4803973/publications.pdf>

Version: 2024-02-01

119  
papers

14,147  
citations

22132

59  
h-index

19726

117  
g-index

121  
all docs

121  
docs citations

121  
times ranked

21710  
citing authors

#	ARTICLE	IF	CITATIONS
1	Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET. <i>Nature Medicine</i> , 2012, 18, 883-891.	15.2	3,098
2	Epithelial-Mesenchymal Transition in Breast Cancer Relates to the Basal-like Phenotype. <i>Cancer Research</i> , 2008, 68, 989-997.	0.4	934
3	Metastatic Colonization Requires the Repression of the Epithelial-Mesenchymal Transition Inducer Prrx1. <i>Cancer Cell</i> , 2012, 22, 709-724.	7.7	832
4	Transcriptional regulation of cell polarity in EMT and cancer. <i>Oncogene</i> , 2008, 27, 6958-6969.	2.6	528
5	Correlation of Snail expression with histological grade and lymph node status in breast carcinomas. <i>Oncogene</i> , 2002, 21, 3241-3246.	2.6	522
6	Genetic Profiling of Epithelial Cells Expressing E-Cadherin Repressors Reveals a Distinct Role for Snail, Slug, and E47 Factors in Epithelial-Mesenchymal Transition. <i>Cancer Research</i> , 2006, 66, 9543-9556.	0.4	285
7	Combined Epidermal Growth Factor Receptor Targeting with the Tyrosine Kinase Inhibitor Gefitinib (ZD1839) and the Monoclonal Antibody Cetuximab (IMC-C225). <i>Clinical Cancer Research</i> , 2004, 10, 6487-6501.	3.2	273
8	Abnormalities of the APC/ $\beta$ -catenin pathway in endometrial cancer. <i>Oncogene</i> , 2002, 21, 7981-7990.	2.6	252
9	$\beta$ -Catenin Expression Pattern in Stage I and II Ovarian Carcinomas. <i>American Journal of Pathology</i> , 1999, 155, 527-536.	1.9	217
10	Sox2: a possible driver of the basal-like phenotype in sporadic breast cancer. <i>Modern Pathology</i> , 2007, 20, 474-481.	2.9	209
11	<sc>EMT</sc>: Present and future in clinical oncology. <i>Molecular Oncology</i> , 2017, 11, 718-738.	2.1	205
12	MicroRNA signature of the epithelial-mesenchymal transition in endometrial carcinosarcoma. <i>Journal of Pathology</i> , 2011, 223, 72-80.	2.1	194
13	Lysyl Oxidase-Like 2 as a New Poor Prognosis Marker of Squamous Cell Carcinomas. <i>Cancer Research</i> , 2008, 68, 4541-4550.	0.4	192
14	Epigenetic and genetic alterations of APC and CDH1 genes in lobular breast cancer: Relationships with abnormal E-cadherin and catenin expression and microsatellite instability. <i>International Journal of Cancer</i> , 2003, 106, 208-215.	2.3	186
15	Cytoplasmic localization of p120 <sup>ctn</sup> and E-cadherin loss characterize lobular breast carcinoma from preinvasive to metastatic lesions. <i>Oncogene</i> , 2004, 23, 3272-3283.	2.6	185
16	The morphological and molecular features of the epithelial-to-mesenchymal transition. <i>Nature Protocols</i> , 2009, 4, 1591-1613.	5.5	185
17	SNAIL1 Is Required for Tumor Growth and Lymph Node Metastasis of Human Breast Carcinoma MDA-MB-231 Cells. <i>Cancer Research</i> , 2007, 67, 11721-11731.	0.4	184
18	Cannabinoids reduce ErbB2-driven breast cancer progression through Akt inhibition. <i>Molecular Cancer</i> , 2010, 9, 196.	7.9	156

#	ARTICLE	IF	CITATIONS
19	Tiling Path Genomic Profiling of Grade 3 Invasive Ductal Breast Cancers. <i>Clinical Cancer Research</i> , 2009, 15, 2711-2722.	3.2	152
20	Lysyl oxidase-like 2 (LOXL2), a new regulator of cell polarity required for metastatic dissemination of basal-like breast carcinomas. <i>EMBO Molecular Medicine</i> , 2011, 3, 528-544.	3.3	150
21	Endometrial carcinoma: molecular alterations involved in tumor development and progression. <i>Oncogene</i> , 2013, 32, 403-413.	2.6	148
22	Role of microRNA in epithelial to mesenchymal transition and metastasis and clinical perspectives. <i>Cancer Management and Research</i> , 2014, 6, 205.	0.9	144
23	Gasdermin-B Promotes Invasion and Metastasis in Breast Cancer Cells. <i>PLoS ONE</i> , 2014, 9, e90099.	1.1	141
24	$\beta$ -Catenin Expression Pattern, $\beta$ -Catenin Gene Mutations, and Microsatellite Instability in Endometrioid Ovarian Carcinomas and Synchronous Endometrial Carcinomas. <i>Diagnostic Molecular Pathology</i> , 2001, 10, 116-122.	2.1	138
25	Molecular profiling of docetaxel cytotoxicity in breast cancer cells: uncoupling of aberrant mitosis and apoptosis. <i>Oncogene</i> , 2007, 26, 2902-2913.	2.6	127
26	beta-catenin expression in pilomatrixomas. Relationship with beta-catenin gene mutations and comparison with beta-catenin expression in normal hair follicles. <i>British Journal of Dermatology</i> , 2001, 145, 576-581.	1.4	122
27	Abnormalities of E- and P-cadherin and catenin ( $\beta$ -, $\gamma$ -catenin, and p120ctn) expression in endometrial cancer and endometrial atypical hyperplasia. <i>Journal of Pathology</i> , 2003, 199, 471-478.	2.1	121
28	Lysyl Oxidase-like Protein LOXL2 Promotes Lung Metastasis of Breast Cancer. <i>Cancer Research</i> , 2017, 77, 5846-5859.	0.4	117
29	Exosome-mimetic nanoplatforms for targeted cancer drug delivery. <i>Journal of Nanobiotechnology</i> , 2019, 17, 85.	4.2	117
30	Prostaglandin E2 Leads to the Acquisition of DNMT3A-Dependent Tolerogenic Functions in Human Myeloid-Derived Suppressor Cells. <i>Cell Reports</i> , 2017, 21, 154-167.	2.9	116
31	The class I bHLH factors E2-2A and E2-2B regulate EMT. <i>Journal of Cell Science</i> , 2009, 122, 1014-1024.	1.2	110
32	Cyclin D1 gene (CCND1) mutations in endometrial cancer. <i>Oncogene</i> , 2003, 22, 6115-6118.	2.6	107
33	Microsatellite instability, MLH-1 promoter hypermethylation, and frameshift mutations at coding mononucleotide repeat microsatellites in ovarian tumors. <i>Cancer</i> , 2001, 92, 2829-2836.	2.0	103
34	Snai1 and Snai2 collaborate on tumor growth and metastasis properties of mouse skin carcinoma cell lines. <i>Oncogene</i> , 2008, 27, 4690-4701.	2.6	101
35	Inactivation of the Candidate Tumor Suppressor Par-4 in Endometrial Cancer. <i>Cancer Research</i> , 2007, 67, 1927-1934.	0.4	100
36	Role of Cannabinoid Receptor CB2 in HER2 Pro-oncogenic Signaling in Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv077.	3.0	98

#	ARTICLE	IF	CITATIONS
37	The EMT signaling pathways in endometrial carcinoma. <i>Clinical and Translational Oncology</i> , 2012, 14, 715-720.	1.2	95
38	Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas. <i>Journal of Clinical Pathology</i> , 2006, 60, 1006-1012.	1.0	93
39	LOXL2 drives epithelial-mesenchymal transition via activation of IRE1-XBP1 signalling pathway. <i>Scientific Reports</i> , 2017, 7, 44988.	1.6	93
40	EFNA3 long noncoding RNAs induced by hypoxia promote metastatic dissemination. <i>Oncogene</i> , 2015, 34, 2609-2620.	2.6	91
41	Molecular profiling of circulating tumor cells links plasticity to the metastatic process in endometrial cancer. <i>Molecular Cancer</i> , 2014, 13, 223.	7.9	88
42	The Prognostic Significance of P-Cadherin in Infiltrating Ductal Breast Carcinoma. <i>Modern Pathology</i> , 2001, 14, 650-654.	2.9	85
43	Gasdermin B expression predicts poor clinical outcome in HER2-positive breast cancer. <i>Oncotarget</i> , 2016, 7, 56295-56308.	0.8	83
44	Lysyl oxidase-like 2 represses Notch1 expression in the skin to promote squamous cell carcinoma progression. <i>EMBO Journal</i> , 2015, 34, 1090-1109.	3.5	79
45	Intracellular Delivery of an Antibody Targeting Gasdermin-B Reduces HER2 Breast Cancer Aggressiveness. <i>Clinical Cancer Research</i> , 2019, 25, 4846-4858.	3.2	79
46	LOXL2 in epithelial cell plasticity and tumor progression. <i>Future Oncology</i> , 2012, 8, 1095-1108.	1.1	78
47	Distinct Molecular Alterations in Complex Endometrial Hyperplasia (CEH) With and Without Immature Squamous Metaplasia (Squamous Morules). <i>American Journal of Surgical Pathology</i> , 2005, 29, 1322-1329.	2.1	75
48	Lysyl oxidase-like 2 (LOXL2) and E47 EMT factor: novel partners in E-cadherin repression and early metastasis colonization. <i>Oncogene</i> , 2015, 34, 951-964.	2.6	75
49	Transcriptional profiling of MCF7 breast cancer cells in response to 5-Fluorouracil: Relationship with cell cycle changes and apoptosis, and identification of novel targets of p53. <i>International Journal of Cancer</i> , 2006, 119, 1164-1175.	2.3	74
50	Pathogenetic Pathways in Ovarian Endometrioid Adenocarcinoma. <i>American Journal of Surgical Pathology</i> , 2009, 33, 1157-1163.	2.1	72
51	Expression of cadherins and catenins correlates with distinct histologic types of ovarian carcinomas. <i>Human Pathology</i> , 2006, 37, 1042-1049.	1.1	69
52	High frequency of $\beta$ -catenin mutations in borderline endometrioid tumours of the ovary. <i>Journal of Pathology</i> , 2006, 208, 708-713.	2.1	67
53	A Novel Human Ghrelin Variant (In1-Chrelin) and Ghrelin-O-Acyltransferase Are Overexpressed in Breast Cancer: Potential Pathophysiological Relevance. <i>PLoS ONE</i> , 2011, 6, e23302.	1.1	67
54	JunD is involved in the antiproliferative effect of $\delta^9$ -tetrahydrocannabinol on human breast cancer cells. <i>Oncogene</i> , 2008, 27, 5033-5044.	2.6	66

#	ARTICLE	IF	CITATIONS
55	A core microRNA signature associated with inducers of the epithelial-to-mesenchymal transition. <i>Journal of Pathology</i> , 2014, 232, 319-329.	2.1	66
56	The new truncated somatostatin receptor variant sst5TMD4 is associated to poor prognosis in breast cancer and increases malignancy in MCF-7 cells. <i>Oncogene</i> , 2012, 31, 2049-2061.	2.6	65
57	MicroRNA-Dependent Regulation of Transcription in Non-Small Cell Lung Cancer. <i>PLoS ONE</i> , 2014, 9, e90524.	1.1	65
58	Gene expression profiling of breast cancer cells in response to gemcitabine: NF- $\kappa$ B pathway activation as a potential mechanism of resistance. <i>Breast Cancer Research and Treatment</i> , 2007, 102, 157-172.	1.1	63
59	Sporadic Invasive Breast Carcinomas With Medullary Features Display a Basal-like Phenotype. <i>American Journal of Surgical Pathology</i> , 2007, 31, 501-508.	2.1	62
60	Functional characterization of E- and P-cadherin in invasive breast cancer cells. <i>BMC Cancer</i> , 2009, 9, 74.	1.1	61
61	LOXL2 catalytically inactive mutants mediate epithelial-to-mesenchymal transition. <i>Biology Open</i> , 2014, 3, 129-137.	0.6	60
62	Cyclin E gene (CCNE) amplification and hCDC4 mutations in endometrial carcinoma. <i>Journal of Pathology</i> , 2003, 201, 589-595.	2.1	56
63	$\beta$ - And $\beta$ -catenin expression in endometrial carcinoma. Relationship with clinicopathological features and microsatellite instability. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2001, 438, 464-469.	1.4	52
64	Zeb1 and <i>S</i> nail1 engage miR-200f transcriptional and epigenetic regulation during EMT. <i>International Journal of Cancer</i> , 2015, 136, E62-73.	2.3	52
65	MicroRNA-654-5p suppresses ovarian cancer development impacting on MYC, WNT and AKT pathways. <i>Oncogene</i> , 2019, 38, 6035-6050.	2.6	49
66	E47 and Id1 Interplay in Epithelial-Mesenchymal Transition. <i>PLoS ONE</i> , 2013, 8, e59948.	1.1	46
67	Activated leukocyte cell adhesion molecule ( <i>ALCAM</i> ) is a marker of recurrence and promotes cell migration, invasion, and metastasis in early-stage endometrioid endometrial cancer. <i>Journal of Pathology</i> , 2017, 241, 475-487.	2.1	42
68	Contribution of Epithelial Plasticity to Therapy Resistance. <i>Journal of Clinical Medicine</i> , 2019, 8, 676.	1.0	42
69	$\beta$ -Catenin expression pattern in primary oesophageal squamous cell carcinoma. Relationship with clinicopathologic features and clinical outcome. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2000, 437, 599-604.	1.4	41
70	Simultaneous inactivation of Par-4 and PTEN in vivo leads to synergistic NF- $\kappa$ B activation and invasive prostate carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 12962-12967.	3.3	40
71	Therapeutic targeting of HER2 <sup>CB</sup> heteromers in HER2-positive breast cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 3863-3872.	3.3	40
72	Annexin A2 as predictor biomarker of recurrent disease in endometrial cancer. <i>International Journal of Cancer</i> , 2015, 136, 1863-1873.	2.3	39

#	ARTICLE	IF	CITATIONS
73	Tissue Microarray Immunohistochemical Expression Analysis of Mismatch Repair (hMLH1 and hMSH2) Tj ETQq1 1 0.784314 rgBT /Over Microsatellite Instability. <i>Modern Pathology</i> , 2003, 16, 1148-1158.	2.9	38
74	Genetic analysis of uterine aspirates improves the diagnostic value and captures the intra-tumor heterogeneity of endometrial cancers. <i>Modern Pathology</i> , 2017, 30, 134-145.	2.9	36
75	Molecular alterations associated with cyclin d1 overexpression in endometrial cancer. <i>International Journal of Cancer</i> , 2004, 110, 194-200.	2.3	35
76	Premalignant SOX2 overexpression in the fallopian tubes of ovarian cancer patients: Discovery and validation studies. <i>EBioMedicine</i> , 2016, 10, 137-149.	2.7	34
77	Stem cell-like transcriptional reprogramming mediates metastatic resistance to mTOR inhibition. <i>Oncogene</i> , 2017, 36, 2737-2749.	2.6	34
78	The tumor suppressor ING1 contributes to epigenetic control of cellular senescence. <i>Aging Cell</i> , 2011, 10, 158-171.	3.0	32
79	KSR1 Is Overexpressed in Endometrial Carcinoma and Regulates Proliferation and TRAIL-Induced Apoptosis by Modulating FLIP Levels. <i>American Journal of Pathology</i> , 2011, 178, 1529-1543.	1.9	30
80	Molecular events in endometrial carcinosarcomas and the role of high mobility group AT-hook 2 in endometrial carcinogenesis. <i>Human Pathology</i> , 2013, 44, 244-254.	1.1	30
81	MicroRNAs as prognostic markers in ovarian cancer. <i>Molecular and Cellular Endocrinology</i> , 2014, 390, 73-84.	1.6	30
82	Chromatin remodelling and DNA repair genes are frequently mutated in endometrioid endometrial carcinoma. <i>International Journal of Cancer</i> , 2017, 140, 1551-1563.	2.3	30
83	Extracellular Vesicles-Based Biomarkers Represent a Promising Liquid Biopsy in Endometrial Cancer. <i>Cancers</i> , 2019, 11, 2000.	1.7	30
84	Sin3b Interacts with Myc and Decreases Myc Levels. <i>Journal of Biological Chemistry</i> , 2014, 289, 22221-22236.	1.6	29
85	A Role for CXCR4 in Peritoneal and Hematogenous Ovarian Cancer Dissemination. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 532-543.	1.9	28
86	Interplay between YB-1 and IL-6 promotes the metastatic phenotype in breast cancer cells. <i>Oncotarget</i> , 2015, 6, 38239-38256.	0.8	28
87	Human equilibrative nucleoside transporter-1 (hENT1) is required for the transcriptomic response of the nucleoside-derived drug 5-DFUR in breast cancer MCF7 cells. <i>Biochemical Pharmacology</i> , 2006, 72, 1646-1656.	2.0	27
88	Tumor Heterogeneity in Endometrial Carcinoma: Practical Consequences. <i>Pathobiology</i> , 2018, 85, 35-40.	1.9	26
89	Circulating Tumor Cells Characterization Revealed TIMP1 as a Potential Therapeutic Target in Ovarian Cancer. <i>Cells</i> , 2020, 9, 1218.	1.8	25
90	PAI-1 and functional blockade of SNAI1 in breast cancer cell migration. <i>Breast Cancer Research</i> , 2008, 10, R100.	2.2	23

#	ARTICLE	IF	CITATIONS
91	A role for the transducer of the Hippo pathway, TAZ, in the development of aggressive types of endometrial cancer. <i>Modern Pathology</i> , 2015, 28, 1492-1503.	2.9	23
92	Genomic Profiling of Uterine Aspirates and cfDNA as an Integrative Liquid Biopsy Strategy in Endometrial Cancer. <i>Journal of Clinical Medicine</i> , 2020, 9, 585.	1.0	23
93	Clinicopathological and molecular analysis of endometrial carcinoma associated with tamoxifen. <i>Modern Pathology</i> , 2008, 21, 925-936.	2.9	22
94	Low Frequency of BRAF Mutations in Endometrial and in Cervical Carcinomas. <i>Clinical Cancer Research</i> , 2006, 12, 3865-3866.	3.2	20
95	In1-ghrelin splicing variant is associated with reduced disease-free survival of breast cancer patients and increases malignancy of breast cancer cells lines. <i>Carcinogenesis</i> , 2018, 39, 447-457.	1.3	19
96	A 9-protein biomarker molecular signature for predicting histologic type in endometrial carcinoma by immunohistochemistry. <i>Human Pathology</i> , 2014, 45, 2394-2403.	1.1	18
97	E2A Modulates Stemness, Metastasis, and Therapeutic Resistance of Breast Cancer. <i>Cancer Research</i> , 2021, 81, 4529-4544.	0.4	18
98	ING4 regulates a secretory phenotype in primary fibroblasts with dual effects on cell proliferation and tumor growth. <i>Oncogene</i> , 2014, 33, 1945-1953.	2.6	17
99	Looking for a Better Characterization of Triple-Negative Breast Cancer by Means of Circulating Tumor Cells. <i>Journal of Clinical Medicine</i> , 2020, 9, 353.	1.0	17
100	Correlation of p53 oncoprotein expression with chemotherapy response in small cell lung carcinomas. <i>Lung Cancer</i> , 2001, 34, 67-74.	0.9	16
101	â€œNewâ€•molecular taxonomy in breast cancer. <i>Clinical and Translational Oncology</i> , 2008, 10, 777-785.	1.2	16
102	Intra-tumor heterogeneity in TP53 null High Grade Serous Ovarian Carcinoma progression. <i>BMC Cancer</i> , 2015, 15, 940.	1.1	16
103	The truncated somatostatin receptor sst5TMD4 stimulates the angiogenic process and is associated to lymphatic metastasis and disease-free survival in breast cancer patients. <i>Oncotarget</i> , 2016, 7, 60110-60122.	0.8	16
104	The homeoprotein SIX1 controls cellular senescence through the regulation of p16INK4A and differentiation-related genes. <i>Oncogene</i> , 2016, 35, 3485-3494.	2.6	15
105	The Ras-related gene ERAS is involved in human and murine breast cancer. <i>Scientific Reports</i> , 2018, 8, 13038.	1.6	15
106	Impact of notch signaling on the prognosis of patients with head and neck squamous cell carcinoma. <i>Oral Oncology</i> , 2020, 110, 105003.	0.8	12
107	Insight updating of the molecular hallmarks in ovarian carcinoma. <i>European Journal of Cancer, Supplement</i> , 2020, 15, 16-26.	2.2	12
108	Characterisation of tumoral markers correlated with ErbB2 (HER2/Neu) overexpression and metastasis in breast cancer. <i>Proteomics - Clinical Applications</i> , 2008, 2, 1313-1326.	0.8	11

#	ARTICLE	IF	CITATIONS
109	Clinical validation of a novel quantitative assay for the detection of MGMT methylation in glioblastoma patients. <i>Clinical Epigenetics</i> , 2021, 13, 52.	1.8	9
110	Intratumor genetic heterogeneity and clonal evolution to decode endometrial cancer progression. <i>Oncogene</i> , 2022, 41, 1835-1850.	2.6	9
111	Prostaglandin F <sub>2</sub> $\alpha$ -induced Prostate Transmembrane Protein, Androgen Induced 1 mediates ovarian cancer progression increasing epithelial plasticity. <i>Neoplasia</i> , 2019, 21, 1073-1084.	2.3	8
112	Isobolographic Analysis Demonstrates the Additive and Synergistic Effects of Gemcitabine Combined with Fucoidan in Uterine Sarcomas and Carcinosarcoma Cells. <i>Cancers</i> , 2020, 12, 107.	1.7	8
113	Gemcitabine and Selected mTOR Inhibitors in Uterine Sarcomas and Carcinosarcoma Cells- an Isobolographic Analysis. <i>International Journal of Medical Sciences</i> , 2020, 17, 2987-2997.	1.1	8
114	Lox13 Promotes Melanoma Progression and Dissemination Influencing Cell Plasticity and Survival. <i>Cancers</i> , 2022, 14, 1200.	1.7	8
115	Re: Scholten et al. Nuclear $\beta$ -catenin is a molecular feature of type I endometrial carcinoma. <i>J Pathol</i> 2003; 201: 460-465. <i>Journal of Pathology</i> , 2004, 202, 511-512.	2.1	7
116	Cancer network activity associated with therapeutic response and synergism. <i>Genome Medicine</i> , 2016, 8, 88.	3.6	7
117	Loss of Snail2 favors skin tumor progression by promoting the recruitment of myeloid progenitors. <i>Carcinogenesis</i> , 2015, 36, 585-597.	1.3	5
118	Biological Effects of Temozolomide on the mTOR Pathway in Endometrial Carcinoma. <i>International Journal of Gynecological Cancer</i> , 2016, , 1.	1.2	5
119	Isolation and characterization of casein kinase I from <i>Dictyostelium discoideum</i> . <i>Biochemical Journal</i> , 2000, 349, 527.	1.7	3